What is the catalog number for Indigopurpurin-d4?

The catalog number for Indigopurpurin-d4 is CS-T-103703.

What sizes are available for Indigopurpurin-d4?

Indigopurpurin-d4 is available in the following size(s): 1 Each.

Is Indigopurpurin-d4 in stock?

Indigopurpurin-d4 is currently made to order / not held in immediate stock. Contact us for lead time.

Where can I find the safety data sheet (SDS/MSDS) for Indigopurpurin-d4?

The safety data sheet for Indigopurpurin-d4 is available here: https://msds_v1.clearsynth.com/msds.asp?catnumber=CS-T-103703.

Indigopurpurin-d4

Indigopurpurin-d4 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Indigopurpurin. The product is supplied by Clearsynth under CAT No. CS-T-103703. Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.

Product Specifications

Overview

Indigopurpurin-d4 is labeled is Indigopurpurin (I521350) which is a purple 3,2-bisindole derivative and was shown to exhibit inhibitory allergic contact dermatitis via regulating T helper (Th) -mediated immune system in DNCB-induced model. A possible glycogen synthase kinase-3 (GSK-3) inhibitor the active component of a traditional Congolese antiepilepsy treatment.

Synonyms

Indigopurpurin-d4

Molecular Formula

C 16 H 6 D 4 N 2 O 2

Molecular Weight

266.29

Additionnal Information

Indigopurpurin-d4 is supplied with detailed characterization data compliant with regulatory guideline. Indigopurpurin-d4 can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Indigopurpurin.

Storage Conditions

Refer MSDS for complete information.

Applications Notes

Indigopurpurin-d4 is labeled is Indigopurpurin (I521350) which is a purple 3,2-bisindole derivative and was shown to exhibit inhibitory allergic contact dermatitis via regulating T helper (Th) -mediated immune system in DNCB-induced model. A possible glycogen synthase kinase-3 (GSK-3) inhibitor the active component of a traditional Congolese antiepilepsy treatment.